Mounjaro/Zepbound and Wegovy/Ozempic are basically the same drug — they're all GLP-1 agonists. Tirzepatide just has slightly different chemistry but the same mechanism. The choice is just about cost.

The strongest form of the claim is that both molecules sit in the broader incretin-receptor-agonist class and share substantial pharmacology. That part is true. Both semaglutide and tirzepatide delay gastric emptying, stimulate glucose-dependent insulin secretion at the pancreatic β-cell, and act on hypothalamic and brainstem appetite circuits to reduce caloric intake. For a patient who tolerates semaglutide well, the qualitative experience on tirzepatide — appetite suppression in the early weeks, GI side effects during titration, gradual weight loss across months — is broadly recognisable rather than alien. The class-membership claim is not contested. The error is the next step in the syllogism: that because both engage GLP-1 receptor signalling, they engage the same receptor population and produce the same downstream pharmacology. That step does not follow.

The receptor pharmacology is genuinely different, not "slightly different chemistry." Semaglutide is a 31-residue GLP-1 analog with high affinity for the GLP-1 receptor and minimal cross-reactivity with other incretin receptors (Lau et al. 2015). Tirzepatide is a 39-residue synthetic peptide engineered from the native glucose-dependent insulinotropic polypeptide (GIP) backbone with intentional binding to both the GIP receptor and the GLP-1 receptor — a deliberate second receptor target rather than an incidental off-target effect (Coskun et al., Mol Metab 2018, 18:3–14). The Coskun paper is the foundational pharmacology characterisation: LY3298176 (the development name) activates both GIP and GLP-1 receptor signalling in vitro, produces glucose-dependent insulin secretion through both receptors in mice, and produces weight and food-intake reductions in chronic mouse administration that are significantly greater than the comparator GLP-1 receptor agonist. The molecule was engineered to do something the GLP-1-only class cannot.

What GIP receptor activation adds. GIP receptors are expressed on pancreatic β-cells, adipocytes, and selected central nervous system populations. Activation contributes a second incretin signal at the β-cell, modifies adipocyte insulin sensitivity and lipid handling, and appears to alter nausea-pathway signalling in ways that may explain the slightly improved tolerability of the higher-effect tirzepatide doses relative to what equivalent GLP-1 dose escalation would produce. A subsequent receptor-pharmacology paper (Willard et al., JCI Insight 2020, 5:e140532) describes tirzepatide as an "imbalanced and biased" dual agonist — meaning it engages the GIP receptor with native-GIP-like properties but engages the GLP-1 receptor with a biased signalling profile that favours certain downstream pathways. The mechanistic picture is unsettled in detail and the relative contributions of each receptor to clinical effect are still being parsed. What is settled is that the GIP component is real, intentional, and absent from semaglutide.

The head-to-head trial quantifies the difference. SURPASS-2 is the only major head-to-head trial of the modern GLP-1 class — 1,879 type-2-diabetes patients on metformin background, 40 weeks, randomised across tirzepatide 5/10/15 mg and semaglutide 1 mg. Tirzepatide met both noninferiority and superiority at all three doses on HbA1c (estimated mean change −2.01, −2.24, and −2.30 percentage points versus −1.86 on semaglutide 1 mg), and the 15-mg arm produced roughly twice the weight loss of the semaglutide 1-mg arm. The honest caveat — named on the SURPASS-2 page itself — is that the semaglutide comparator was the 1-mg type-2-diabetes dose rather than the 2.4-mg dose used for chronic weight management in the STEP-1 trial, and a head-to-head against semaglutide 2.4 mg has not been published as of mid-2026. The current best estimate of the comparative obesity magnitudes is therefore the cross-trial comparison: SURMOUNT-1's approximately 22.5% mean loss at tirzepatide 15 mg over 72 weeks versus STEP-1's approximately 14.9% mean loss at semaglutide 2.4 mg over 68 weeks, in similar non-diabetic populations. Cross-trial comparison is not head-to-head, but the magnitude separation is large enough that the equivalence framing does not survive even the most generous reading.

Side-effect profiles differ in magnitude rather than kind. Both molecules produce the same gastrointestinal adverse-event pattern: nausea, vomiting, diarrhea, constipation, concentrated during dose escalation, typically mild-to-moderate. SURMOUNT-1 reported discontinuation due to adverse events ranging from 2.6% on placebo to 7.1% on tirzepatide 10 mg; STEP-1 reported a roughly similar profile for semaglutide 2.4 mg. The class-level signals — gallbladder disease, pancreatitis, the FDA boxed warning for medullary thyroid carcinoma based on rodent C-cell tumour data — apply to both molecules. The 2024 nonarteritic anterior ischemic optic neuropathy signal that emerged in semaglutide observational data has not been definitively replicated for tirzepatide as of 2026, though the underlying mechanism (if real) is likely a class effect rather than a molecule-specific one. The hypothesis that GIP-mediated lean-mass preservation differentiates tirzepatide from semaglutide on body composition is partially supported in body-composition substudies and synthesised across the class in Batsis et al. 2026 but is not definitive. The summary is that the two molecules share the same adverse-event vocabulary; the magnitude at any given clinically meaningful dose differs in ways that matter for individual patients.

The cardiovascular-outcome positioning is molecule-specific. SUSTAIN-6 showed semaglutide reduced the composite cardiovascular endpoint by 26% in type-2-diabetes patients at high cardiovascular risk. SELECT extended the signal to non-diabetic patients with established cardiovascular disease and BMI ≥27, reporting a 20% reduction in the composite MACE endpoint over a mean 40-month follow-up. The tirzepatide cardiovascular outcome trial — SURPASS-CVOT — was published in late 2025 (Nicholls et al., N Engl J Med 2025, NEJMoa2505928), randomising 13,165 type-2-diabetes patients with established cardiovascular disease to tirzepatide up to 15 mg or dulaglutide 1.5 mg over a median of approximately 4 years. The primary composite occurred in 12.2% of the tirzepatide group versus 13.1% of dulaglutide (HR 0.92), meeting noninferiority but not superiority versus an active GLP-1RA comparator; tirzepatide also produced a 16% reduction in all-cause mortality (HR 0.84). The trial answers a different question than SUSTAIN-6 or SELECT: SURPASS-CVOT compares tirzepatide to an active GLP-1RA, not to placebo, so it cannot tell a patient how much cardiovascular benefit either molecule produces relative to no incretin therapy. The two evidence bases are not directly comparable and support different clinical positioning for different patient populations.

Both manufacturers are building on, not finalising, their molecules. The pipeline context complicates any "tirzepatide is just the next semaglutide" framing. Novo Nordisk is developing CagriSema, a combination of semaglutide and the long-acting amylin analog cagrilintide — adding amylin receptor agonism on top of GLP-1 receptor agonism. Eli Lilly is developing retatrutide, a triple agonist that adds glucagon receptor activation to tirzepatide's GIP/GLP-1 dual agonism. The two companies are layering additional receptor pharmacology on top of their respective platforms because both teams view their current molecules as starting points rather than endpoints. The next generation will differ from the current generation in receptor count and binding profile, not just in salt form, branding, or dose. Treating tirzepatide and semaglutide as the same drug obscures that the field is moving past both of them on the basis of pharmacology differences that the equivalence framing claims do not exist.

The clinical decision is not "just cost." Choosing between semaglutide and tirzepatide depends on patient-specific GI tolerance, insurance coverage and prior-authorisation status, the comorbidity profile that determines whether the SELECT (semaglutide) or SURPASS-CVOT (tirzepatide) cardiovascular evidence applies more directly, prior-medication history, and dose-titration practicality. The compounded-pharmacy distinction applies differently to each molecule — FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025, with different wind-down dates and different ongoing enforcement contests. The dose-response framing applies across both molecules but with different inflection points. The fat-loss decision guide and the GLP-1 receptor pharmacology dossier hold the applied framework for the molecule-level choice.

This page does not argue that tirzepatide is universally superior to semaglutide. SUSTAIN-6 and SELECT remain the load-bearing cardiovascular evidence for the GLP-1 class in populations where no tirzepatide trial yet provides equivalent data; semaglutide's psychiatric and addiction-medicine signals (Klausen 2026 on alcohol use disorder, Gill 2026 on major depressive disorder) are molecule-specific evidence that does not exist for tirzepatide; the cost gap is real and access matters for clinical equity. What this page argues is that "they're basically the same drug" is a regulatory and pharmacological claim that the underlying molecules do not support. The receptor count is different, the engineered pharmacology is different, the head-to-head trial is decisive on the diabetes endpoint, the cross-trial obesity comparison is consistent with the head-to-head finding, the cardiovascular evidence bases are not interchangeable, and both manufacturers' pipelines are explicitly built on the premise that GLP-1 monoagonism and GLP-1/GIP dual agonism are different starting points. The choice is a real prescribing decision with real molecule-level information to carry into it.